Svr Drugs Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 5.61 Cr
as on 15-11-2024
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 27.89 Cr
as on 15-11-2024
- Satisfied Charges ₹ 2.00 Cr
as on 15-11-2024
- Revenue 33.74%
(FY 2023)
- Profit 19.10%
(FY 2023)
- Ebitda 13.74%
(FY 2023)
- Net Worth 7.46%
(FY 2023)
- Total Assets 15.55%
(FY 2023)
About Svr Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 5.61 Cr.
The company currently has active open charges totaling ₹27.89 Cr. The company has closed loans amounting to ₹2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Srinivasulu Kavuturu, Nageswara Pinneti, Nagadurga Pinneti, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232AP2010PTC070173
- Company No.
070173
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Aug 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Svr Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nageswara Pinneti  | Managing Director | 29-Nov-2010 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srinivasulu Kavuturu | Director | 25-Apr-2012 | Current |
| Nagadurga Pinneti | Whole-Time Director | 25-Apr-2012 | Current |
| Srivani Kavuturu | Director | 16-Aug-2017 | Current |
Financial Performance of Svr Drugs.
Svr Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 33.74% increase. The company also saw a substantial improvement in profitability, with a 19.1% increase in profit. The company's net worth moved up by a moderate rise of 7.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Svr Drugs?
In 2023, Svr Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
S.V.R. Laboratories Private LimitedActive 21 years 3 monthsSrinivasulu Kavuturu, Nageswara Pinneti and 2 more are mutual person
- Srinag Pharma Private LimitedActive 7 years 3 months
Srinivasulu Kavuturu and Nageswara Pinneti are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 13 Feb 2015 | ₹2.00 Cr | Open |
Others Creation Date: 09 Mar 2012 | ₹25.89 Cr | Open |
Union Bank Of India Creation Date: 08 Nov 2014 | ₹2.00 Cr | Satisfied |
How Many Employees Work at Svr Drugs?
Svr Drugs has a workforce of 216 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Svr Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Svr Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
